evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

40 questions · 40 findings · 12 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 13 · 32.5%GRADE not reported 1 · 2.5%Very low 2 · 5%Low 5 · 12.5%Moderate 12 · 30%High 7 · 17.5%

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy alone

Overall survival (OS) · platinum‐sensitive recurrent EOC

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in overall survival (OS) compared with chemotherapy (low certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo (maintenance therapy)

Overall survival (OS) · platinum‐sensitive recurrent EOC

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in overall survival (OS) compared with placebo after chemotherapy (maintenance therapy) (moderate certainty).

1 finding from 1 review

Lifestyle interventions vs placebo or usual care

Overall survival (24 months) · weight reduction in obesity to improve survival in women with endometrial cancer

It is very uncertain whether summary of findings table ‐ Lifestyle intervention changes overall survival (24 months) compared with usual care compared to placebo (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV)

Overall survival · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6… showed no clear difference in overall survival compared with low‐risk standard (2 doses, 2500 IU/m2, IV) (moderate certainty).

1 finding from 1 review

Summary of findings table (subcomparison 3): chemotherapy agent(s) plus control intervention vs control intervention

Overall survival · palliative participants with esophageal and GE‐junction carcinoma

Summary of findings table (subcomparison 3): chemotherapy agent(s)… probably leads to lower overall survival compared with control intervention alone (moderate certainty).

1 finding from 1 review

Summary of findings table (subcomparison 4): targeted therapy agent plus control intervention vs control intervention

Overall survival · palliative participants with esophageal and GE‐junction carcinoma

Summary of findings table (subcomparison 4): targeted therapy agent… leads to lower overall survival compared with control intervention alone (high certainty).

1 finding from 1 review

Summary of findings table (subcomparison 5): chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

Overall survival · palliative participants with esophageal and GE‐junction carcinoma

Summary of findings table: chemotherapy or targeted therapy agent(s)… leads to lower overall survival compared with control intervention alone (high certainty).

1 finding from 1 review

Summary of findings table (subcomparison 1): chemotherapy or targeted therapy plus best supportive care (BSC) vs BSC

Overall survival · palliative participants with esophageal and GE‐junction carcinoma

Summary of findings table (subcomparison 1): chemotherapy or… leads to lower overall survival compared with BSC (high certainty).

1 finding from 1 review

Summary of findings table (subcomparison 5): chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

Overall survival · palliative participants with AC of the esophagus

Summary of findings table (subcomparison 5): chemotherapy or… leads to lower overall survival compared with control intervention alone (high certainty).

1 finding from 1 review

Summary of findings table (subcomparison 5): chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

Overall survival · palliative participants with SCC of the esophagus

Summary of findings table (subcomparison 6): chemotherapy or… leads to lower overall survival compared with control intervention alone (high certainty).

1 finding from 1 review

Summary of findings table (subcomparison 2): second‐line chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

Overall survival · palliative participants with esophageal and GE‐junction carcinoma previously treated with chemotherapy

Summary of findings table (subcomparison 2): second‐line… probably leads to lower overall survival compared with control intervention alone (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Overall survival (at 36 months) · people with newly diagnosed multiple myeloma ineligible for transplant

Summary of findings table ‐ Daratumumab plus standard therapy probably leads to lower overall survival (at 36 months) compared with standard therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Intermittent PEG‐asparaginase treatment (8 doses, 1000 IU/m2, IM) vs continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM)

Overall survival ‐ not reported · children and adolescents (< 18 years of age) with first‐line ALL

The review found no eligible studies for this question.

1 finding from 1 review